Compare ZVIA & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | ONCY |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Pharmaceuticals and Biotechnology |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 109.1M |
| IPO Year | 2021 | 2002 |
| Metric | ZVIA | ONCY |
|---|---|---|
| Price | $1.38 | $0.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.93 | ★ $7.33 |
| AVG Volume (30 Days) | 407.7K | ★ 644.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,259,000.00 | N/A |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $6.87 | $2,505.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $1.11 | $0.73 |
| 52 Week High | $2.81 | $1.51 |
| Indicator | ZVIA | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 53.15 |
| Support Level | $1.27 | $0.85 |
| Resistance Level | $1.53 | $0.87 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 46.73 | 56.29 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.